99.8%
Negative predictive value. A Not Elevated result means lung cancer is very unlikely.
OUR MISSION
Making cancer less deadly through widely accessible early detection.
Making cancer less deadly through widely accessible early detection.
DELFI Diagnostics develops blood-based tests that use genomics and AI-driven machine learning to help detect cancer earlier. Our first test targets lung cancer, where early detection is one of the greatest opportunities to save lives.
WHY THIS MATTERS NOW
Lung cancer is the leading cause of cancer mortality, largely because it is found late.
Low-dose CT screening works, but most eligible people never get it. Access, cost, and logistics get in the way, including for people with a significant smoking history who qualify for screening under current guidelines.
A blood draw is easier to fit into a normal visit than a scheduled scan. That is the gap DELFI is addressing, not by replacing CT screening, but by making it easier for more people to start.
HOW WE APPROACH IT
One Blood Draw. A Genome-Wide Look at What Cancer Leaves Behind.
DELFI applies whole genome sequencing and machine learning to reveal the signals, or “fingerprint,” that cancer cells leave behind. Circulating cell-free DNA from a routine FirstLook™ Lung blood draw contains this information.
The Data Behind the FirstLook Blood Draw
Test Performance
79
Number needed to screen with an Elevated result to find one lung cancer, vs. 143 for anyone screening-eligible.
5.2x
Higher likelihood of a lung cancer finding on LDCT with an Elevated vs. Not Elevated result.
Source: FirstLook Lung provider data, delfidiagnostics.com.
Real-World Impact — ATS 2026
2.73x
Increase in any lung cancer screening when primary care had access to FirstLook Lung.
1.47x
Increase in LDCT screening, the standard of care, when FirstLook Lung was available.
3,000+ modeled lung cancer deaths preventable over 5 years beyond LDCT screening alone.
Results from the FIRSTLUNG L301 cluster-randomized clinical utility trial (NCT06145750), presented as a late-breaking oral presentation at the American Thoracic Society 2026 International Conference. Davis JM, et al. Am J Respir Crit Care Med 2026;212(Suppl 2):aamag286.212.
WHAT GUIDES THE WORK
Four commitments that shape every decision.
01
Lead With Science
We follow the evidence, including when it slows us down or tells us something we did not expect.
02
Anchored In Pragmatism
We build for what can actually reach patients now, not just what is possible in theory.
03
Build With and For All
Early detection only matters if it reaches the people who are currently missing out on it.
04
We Over I
The science, the mission, and the patient come before individual credit.
WHERE THIS IS HEADED
Lung cancer screening is the start, not the destination.
FirstLook Lung is DELFI’s first widely available blood test for lung cancer screening. The same underlying platform is built to adapt further over time, from screening into monitoring, and from lung cancer to other diseases where a blood draw could catch something early enough to matter.
Making cancer less deadly starts by making detection reachable.
That is the mission behind every test DELFI builds, and the reason we measure success by how many more people get screened, not just how the technology performs in a lab.